2021. Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs). SKIN The Journal of Cutaneous Medicine. 5, 1 (Jan. 2021), s3. DOI:https://doi.org/10.25251/skin.5.supp.3.